Improvement of ixekizumab-related interstitial pneumonia following its discontinuation in a patient with psoriatic arthritis

Eur J Dermatol. 2022 Apr 1;32(2):281-282. doi: 10.1684/ejd.2022.4251.
No abstract available

MeSH terms

  • Antibodies, Monoclonal, Humanized / adverse effects
  • Arthritis, Psoriatic* / drug therapy
  • Dermatologic Agents* / adverse effects
  • Humans
  • Lung Diseases, Interstitial* / chemically induced
  • Lung Diseases, Interstitial* / drug therapy
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal, Humanized
  • Dermatologic Agents
  • ixekizumab